- 60.3% of all randomised ustekinumab-treated patients who entered the long-term extension study were in clinical remission at week 152
- Of those patients who were naïve to TNF... read more
TP Therapeutics announced on 10/24/18 a global collaboration agreement to develop and commercialize a next-generation sequencing (NGS) companion diagnostic (CDx) for repotrectinib, TP... read more
Bain Capital, LP and... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,